SNOA

Sonoma Pharmaceuticals Inc. (SNOA) | Rumor.io

Sonoma Pharmaceuticals

SNOA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,010

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.68

Market capitalization6M

Earnings per share-1.22

Dividend yield (TTM)—

Revenue (annual)19.5M

Net income (annual)-3.2M

Social

What share of all stock conversation is about SNOA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 7

Sonoma Pharmaceuticals' Q1 results showed a 141% increase in U.S. revenue and 60% total revenue growth, with the company reporting its first-ever positive adjusted EBITDA.
The company's strong commercial strategy, growing global adoption of its hypochlorous acid products, and operating leverage are expected to continue driving profitable growth.
Sonoma Pharmaceuticals' Q1 results are considered one of the strongest in years, with the company's stock price experiencing a steady increase following the earnings report.

Generated by AI

Sentiment

Of the messages about SNOA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	93.57% +3.82
Bearish	—	0%	0% 0	6.43% -3.82

Bullish· Aug 7

$SNOA is undervalued at its current market cap of $6 million, making it a prime target for investors looking for a turnaround story with potential for significant growth.
The company's strong fundamentals, including rising sales, improving margins, and approaching profitability, make it an attractive investment opportunity, especially considering its current price.
With a record-breaking quarter featuring 141% U.S. revenue growth, 60% total revenue growth, and first-ever positive adjusted EBITDA, $SNOA is poised for continued profitable growth and is a promising addition to any investment portfolio.

Bearish· Aug 14

$SNOA is experiencing high volatility, with multiple halts and rapid price swings, making it challenging for investors.
The stock has a history of being a "pump and dump" with a tendency to run up on hype and then crash hard, settling at lower prices.
Bears are trying to keep the stock price down, with multiple attempts to take out stops and control the narrative, suggesting strong short interest.

Generated by AI

Topics

Of the messages about SNOA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	8%
Announcements	—	—	—	90%
Earnings	—	—	—	2%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Earnings· Jun 13

$SNOA misses Q4 EPS estimate by $0.34, with an actual loss of $(0.93) vs. estimate of $(0.59).
Revenue for Q4 came in at $3.655M, missing the estimate of $4.49M.
Sonoma Pharmaceuticals cited wholesaler de-stocking as a reason for the decline in revenue, despite prescriptions being filled consistently with expectations.

Announcements· Aug 14

Sonoma Pharmaceuticals' ($SNOA) new HOCl-based diaper rash product has been launched in 3,600 Walmart stores, as well as on Amazon and in major grocery chains.
The product's availability in large retailers marks a significant retail presence for the company and a key step in expanding its over-the-counter product lineup.
The launch has driven a significant increase in the company's stock price, with shares up 77% following the announcement.

Technical Analysis· Aug 14

The chart for SNOA has a potential S/D flip over previous pre-market supply in the upper 5s, with a possible range to $7 or $7.7+.
A double bottom has formed on the SNOA chart, and it has gone "r/g" twice, indicating a possible continuation of the trend.
The MACD for SNOA is in the red, indicating a bearish signal, and the stock has broken below its 200-day moving average, which is not a good sign.

Generated by AI

Community

Of the messages about SNOA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	66.22%
Newcomers	—	100%	100%	33.78%

Regulars· Aug 14

$SNOA is up 107% after announcing the launch of its Diaper Rash product in Walmart and other U.S. chains.
The stock is showing high relative strength, indicating a strong upward trend.
The launch of the Diaper Rash product has triggered a significant increase in trading volume, with the stock breaking out into a new range above $7.

Newcomers· Aug 7

Newcomers are focusing on the significant increase in US sales for Sonoma Pharmaceuticals, Inc., with a +141% growth in the latest quarter.
The company's strong cash reserves and history of significant price appreciation (70-80%) on positive news are drawing attention from newcomers.
The quarterly earnings results are being highlighted as a major positive news event, with some newcomers even considering buying the stock based on the strong results.

Generated by AI

News

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum

1mo agoInvesting.com

Sonoma Pharmaceuticals reports 60% revenue growth in Q1

1mo agoInvesting.com

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new global distributors support continued ...

1mo agofinance.yahoo.com

Also Discussed

Investors talking about SNOA also mention

#	Name	Attention
1	AVAX One Technology Ltd.AGRI	0%0
2	Ainos, Inc.AIMD	0%+0
3	Ensysce Biosciences, Inc. Common StockENSC	0%0
4	Eocene Ltd.GLMD	0%0
5	AGM Group Holdings IncAGMH	0%0
6	BSLK - Bolt Projects Holdings, Inc.	——
7	Tenon Medical, Inc.TNON	0%new
8	LIPO - Lipella Pharmaceuticals Inc.	——
9	AREB - American Rebel Holdings, Inc.	——
10	Virpax Pharmaceuticals Inc.VRPX	0%0

Sonoma Pharmaceuticals Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings. Sonoma Pharmaceuticals markets its products internationally through healthcare and specialty channels, with applications spanning acute and chronic care environments as well as veterinary uses. The company also focuses on advanced tissue care and other topical formulations, making it a niche participant in the broader pharmaceutical and medical products market. Sonoma Pharmaceuticals Inc. is headquartered in Boulder, Colorado.

Website

Location

5445 Conestoga Court

Boulder, CO, 80301

United States

Social

What share of all stock conversation is about SNOA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 7

Sonoma Pharmaceuticals' Q1 results showed a 141% increase in U.S. revenue and 60% total revenue growth, with the company reporting its first-ever positive adjusted EBITDA.
The company's strong commercial strategy, growing global adoption of its hypochlorous acid products, and operating leverage are expected to continue driving profitable growth.
Sonoma Pharmaceuticals' Q1 results are considered one of the strongest in years, with the company's stock price experiencing a steady increase following the earnings report.

Generated by AI

Sentiment

Of the messages about SNOA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	93.57% +3.82
Bearish	—	0%	0% 0	6.43% -3.82

Bullish· Aug 7

$SNOA is undervalued at its current market cap of $6 million, making it a prime target for investors looking for a turnaround story with potential for significant growth.
The company's strong fundamentals, including rising sales, improving margins, and approaching profitability, make it an attractive investment opportunity, especially considering its current price.
With a record-breaking quarter featuring 141% U.S. revenue growth, 60% total revenue growth, and first-ever positive adjusted EBITDA, $SNOA is poised for continued profitable growth and is a promising addition to any investment portfolio.

Bearish· Aug 14

$SNOA is experiencing high volatility, with multiple halts and rapid price swings, making it challenging for investors.
The stock has a history of being a "pump and dump" with a tendency to run up on hype and then crash hard, settling at lower prices.
Bears are trying to keep the stock price down, with multiple attempts to take out stops and control the narrative, suggesting strong short interest.

Generated by AI

Topics

Of the messages about SNOA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	8%
Announcements	—	—	—	90%
Earnings	—	—	—	2%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Earnings· Jun 13

$SNOA misses Q4 EPS estimate by $0.34, with an actual loss of $(0.93) vs. estimate of $(0.59).
Revenue for Q4 came in at $3.655M, missing the estimate of $4.49M.
Sonoma Pharmaceuticals cited wholesaler de-stocking as a reason for the decline in revenue, despite prescriptions being filled consistently with expectations.

Announcements· Aug 14

Sonoma Pharmaceuticals' ($SNOA) new HOCl-based diaper rash product has been launched in 3,600 Walmart stores, as well as on Amazon and in major grocery chains.
The product's availability in large retailers marks a significant retail presence for the company and a key step in expanding its over-the-counter product lineup.
The launch has driven a significant increase in the company's stock price, with shares up 77% following the announcement.

Technical Analysis· Aug 14

The chart for SNOA has a potential S/D flip over previous pre-market supply in the upper 5s, with a possible range to $7 or $7.7+.
A double bottom has formed on the SNOA chart, and it has gone "r/g" twice, indicating a possible continuation of the trend.
The MACD for SNOA is in the red, indicating a bearish signal, and the stock has broken below its 200-day moving average, which is not a good sign.

Generated by AI

Community

Of the messages about SNOA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	66.22%
Newcomers	—	100%	100%	33.78%

Regulars· Aug 14

$SNOA is up 107% after announcing the launch of its Diaper Rash product in Walmart and other U.S. chains.
The stock is showing high relative strength, indicating a strong upward trend.
The launch of the Diaper Rash product has triggered a significant increase in trading volume, with the stock breaking out into a new range above $7.

Newcomers· Aug 7

Newcomers are focusing on the significant increase in US sales for Sonoma Pharmaceuticals, Inc., with a +141% growth in the latest quarter.
The company's strong cash reserves and history of significant price appreciation (70-80%) on positive news are drawing attention from newcomers.
The quarterly earnings results are being highlighted as a major positive news event, with some newcomers even considering buying the stock based on the strong results.

Generated by AI

Sonoma Pharmaceuticals

Social

Aug 7

Bullish· Aug 7

Bearish· Aug 14

Earnings· Jun 13

Announcements· Aug 14

Technical Analysis· Aug 14

Regulars· Aug 14

Newcomers· Aug 7

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum

Sonoma Pharmaceuticals reports 60% revenue growth in Q1

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Also Discussed

Sonoma Pharmaceuticals Inc.

Company Information

Location

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum

Sonoma Pharmaceuticals reports 60% revenue growth in Q1

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Also Discussed

Social

Aug 7

Bullish· Aug 7

Bearish· Aug 14

Earnings· Jun 13

Announcements· Aug 14

Technical Analysis· Aug 14

Regulars· Aug 14

Newcomers· Aug 7